Xeris Biopharma (NASDAQ:XERS) Stock: Insider Steven Pieper Sells 5,000 Shares

by · The Markets Daily

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS – Get Free Report) insider Steven Pieper sold 5,000 shares of the company’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $9.41, for a total value of $47,050.00. Following the completion of the sale, the insider directly owned 1,351,053 shares in the company, valued at approximately $12,713,408.73. The trade was a 0.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

  • On Tuesday, September 1st, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total transaction of $42,500.00.
  • On Wednesday, August 12th, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total transaction of $42,500.00.
  • On Tuesday, July 7th, Steven Pieper sold 27,600 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.52, for a total transaction of $235,152.00.
  • On Monday, July 6th, Steven Pieper sold 17,400 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.50, for a total transaction of $147,900.00.

Xeris Biopharma Stock Down 1.8%

XERS traded down $0.17 during midday trading on Friday, reaching $9.08. The company’s stock had a trading volume of 1,375,716 shares, compared to its average volume of 1,988,684. Xeris Biopharma Holdings, Inc. has a 1 year low of $5.25 and a 1 year high of $11.33. The stock’s 50-day moving average is $8.45 and its 200-day moving average is $7.29. The firm has a market capitalization of $1.66 billion, a price-to-earnings ratio of -82.55 and a beta of 0.53. The company has a current ratio of 1.45, a quick ratio of 1.02 and a debt-to-equity ratio of 17.00.

Xeris Biopharma (NASDAQ:XERS – Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.18) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.19). Xeris Biopharma had a negative net margin of 5.12% and a positive return on equity of 338.21%. The business had revenue of $92.10 million for the quarter, compared to analysts’ expectations of $90.12 million. As a group, research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.07 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the company. Leerink Partners boosted their target price on Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a report on Thursday, September 10th. Barclays raised their price target on Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Weiss Ratings cut shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Finally, Wall Street Zen raised shares of Xeris Biopharma from a “hold” rating to a “buy” rating in a research report on Saturday, September 19th. Four equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Xeris Biopharma currently has an average rating of “Hold” and a consensus target price of $12.80.

Read Our Latest Stock Report on Xeris Biopharma

Institutional Trading of Xeris Biopharma

Several institutional investors have recently added to or reduced their stakes in XERS. BlackRock Inc. purchased a new position in shares of Xeris Biopharma in the second quarter worth $115,042,000. Wellington Management Group LLP boosted its position in shares of Xeris Biopharma by 8.9% during the second quarter. Wellington Management Group LLP now owns 2,365,103 shares of the company’s stock valued at $18,732,000 after buying an additional 193,749 shares during the last quarter. Legal & General Group Plc bought a new stake in Xeris Biopharma in the 2nd quarter worth about $15,941,000. Parkman Healthcare Partners LLC bought a new stake in Xeris Biopharma in the 2nd quarter worth about $14,316,000. Finally, Algert Global LLC raised its position in Xeris Biopharma by 50.6% in the 2nd quarter. Algert Global LLC now owns 1,742,942 shares of the company’s stock worth $13,804,000 after buying an additional 585,984 shares during the last quarter. 42.75% of the stock is currently owned by hedge funds and other institutional investors.

Xeris Biopharma Company Profile

(Get Free Report)

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology, and related rare or chronic conditions. The company uses proprietary formulation technologies designed to deliver medicines that are difficult to formulate or administer through conventional methods, including its XeriSol and XeriJect platforms.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection used to treat severe hypoglycemia; Keveyis (dichlorphenamide), a treatment for primary periodic paralysis; and Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with Cushing’s syndrome.

Further Reading